Patients HCP
This site is for US residents only.

MEET SHARON

Sharon, an actual patient taking TABRECTA, was diagnosed with metastatic non-small cell lung cancer (mNSCLC). At first, she and her husband Donnie were overwhelmed by her diagnosis, but with the guidance of her oncologist and the results of her comprehensive biomarker test, she was able to get a treatment that’s a match for her specific type of cancer. View the videos below to hear Sharon and Donnie's story.

MEET SHARON: Treatment Experience

Sharon describes her experience on TABRECTA as her first-line treatment, including side effects.

MEET SHARON: Taking TABRECTA

Sharon discusses how she incorporates taking TABRECTA into her daily routine.

MEET SHARON: Uncovering MET Exon 14 Skipping Through Comprehensive Biomarker Testing

With the help of her oncologist, Sharon discovers via comprehensive biomarker testing that she has the MET exon 14 skipping biomarker. Thanks to this specific test, her doctor is able to recommend TABRECTA as her first course of treatment.

MEET SHARON: Finding Strength Through Support

Knowing how important the right support system is, Sharon shares how she has found comfort and courage both online and through her fiercest advocate and companion, her husband Donnie.

Important Safety Information

TABRECTA may cause serious side effects. Tell your health care provider right away if you get any of the following:

  • Lung or breathing problems. TABRECTA may cause inflammation of the lungs that can cause death. Tell your health care provider right away if...

Approved Use

TABRECTA is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:

  • has spread to other parts of the body (metastatic), and 
  • whose tumors have an abnormal mesenchymal ...
Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE